Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 8/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | HTR3A | P46098 | 7/20 | 0.44 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.43 |
| ▸ | HTR3B | O95264 | 4/20 | 0.43 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.43 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1284202 | 0.93 | HRH4 (0.44) | HRH4HRH3HTR3AHTR3EHTR3B | |
| SCHEMBL2067822 | 0.82 | MAPT (0.36) | KDM4EALDH1A1CYP1A2 | |
| SCHEMBL743397 | 0.82 | MAPT (0.40) | HRH4ALDH1A1CYP1A2MAP4K4 | |
| SCHEMBL1316269 | 0.81 | MAPT (0.41) | HRH4ALDH1A1CYP1A2MAP4K4 | |
| SCHEMBL19922639 | 0.81 | HRH3 (0.45) | HRH3KDM4EALDH1A1CYP1A2 | |
| SCHEMBL1773335 | 0.81 | HRH3 (0.45) | HRH3KDM4EALDH1A1 | |
| SCHEMBL25260212 | 0.80 | ALDH1A1 (0.35) | ALDH1A1CYP1A2 | |
| SCHEMBL8194170 | 0.80 | MAPT (0.48) | KDM4EALDH1A1 | |
| SCHEMBL8805429 | 0.79 | MAPT (0.49) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL3417957 | 0.78 | ALDH1A1 (0.47) | ALDH1A1MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 271 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381142-A1 | ANTILEISHMANIAL COMPOUNDS, COMPOSITIONS AND USE THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-11-30 | — | — | US | claimed |
| WO-2023230217-A1 | ANTILEISHMANIAL COMPOUNDS, COMPOSITIONS AND USE THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-11-30 | — | — | WO | claimed |
| US-11040981-B2 | Pyrrolotriazine compounds and methods of inhibiting TAM kinases | SYROS PHARMACEUTICALS, INC. (US) | 2021-06-22 | — | — | US | claimed |
| US-20210147431-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | SYROS PHARMACEUTICALS INC (US) | 2021-05-20 | — | — | US | claimed |
| CN-112368285-A | Pyrrolotriazine compounds and methods of inhibiting TAM kinase | 希洛斯医药品股份有限公司 | 2021-02-12 | — | — | CN | claimed |
| EP-3694860-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | Syros Pharmaceuticals, Inc. (US) | 2020-08-19 | — | — | EP | claimed |
| WO-2019074962-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | SYROS PHARMACEUTICALS, INC. (US) | 2019-04-18 | — | — | WO | claimed |
| US-9932324-B2 | Substituted benzimidazolium compounds useful in the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-04-03 | — | — | US | claimed |
| US-20180065969-A1 | THERAPEUTIC AGENT OF ACUTE MYELOID LEUKEMIA CONTAINING 1,3,7-TRISUBSTITUTED 3,4-DIHYDROPYRIMIDO[4,5-D]PYRIMIDINE-2(1H)-ONE DERIVATIVES | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2018-03-08 | — | — | US | claimed |
| US-20180009789-A1 | SUBSTITUTED BENZIMIDAZOLIUM COMPOUNDS USEFUL IN THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-01-11 | — | — | US | claimed |
| US-20030153568-A1 | Benzothiazole derivatives | BASF AKTIENGESELLSCHAFT LUDWIGSHAFEN, GERMANY | 2003-08-14 | — | — | US | claimed |
| US-20030069291-A1 | 3-heterocyclylpropanohydroxamic acid PCP inhibitors | PFIZER INC. | 2003-04-10 | — | — | US | claimed |
| EP-1254123-A1 | 2-BENZOTHIAZOLYL UREA DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | Abbott GmbH & Co. KG (DE) | 2002-11-06 | — | — | EP | claimed |
| WO-2002079200-A1 | 3-HETEROCYCLYLPROPANOHYDROXAMIC ACID AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LIMITED (GB) | 2002-10-10 | — | — | WO | claimed |
| WO-2001057008-A1 | 2-BENZOTHIAZOLYL UREA DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | ABBOTT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG & COMPANY KOMMANDITGESELLSCHAFT (DE) | 2001-08-09 | — | — | WO | claimed |
| EP-0119050-B1 | DIHYDROPYRIDINE ANTI-ISCHAEMIC AND ANTIHYPERTENSIVE AGENTS | Pfizer Limited (GB) | 1989-03-22 | — | — | EP | claimed |
| US-4716168-A | STIMULANTS OF IMMUNE RESPONSE | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1987-12-29 | — | — | US | claimed |
| EP-0187705-A2 | Imidazo(4,5-f)quinolines useful as immunomodulating agents | Norwich Eaton Pharmaceuticals, Inc. (US) | 1986-07-16 | — | — | EP | claimed |
| US-4590195-A | ANTIISCHEMIC AGENTS | PFIZER INC. (US) | 1986-05-20 | — | — | US | claimed |
| EP-0119050-A2 | Dihydropyridine anti-ischaemic and antihypertensive agents | Pfizer Limited (GB) | 1984-09-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147431-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | PLK2, MAP3K5, CAMKK2 | HRH4 1771/4885HRH3 1973/4885HTR3A 1752/4885 |
| US-20230381142-A1 | ANTILEISHMANIAL COMPOUNDS, COMPOSITIONS AND USE THEREOF | MPO, SSB, SGMS2 | HRH4 1088/4885HRH3 1016/4885HTR3A 4773/4885 |
| US-20180065969-A1 | THERAPEUTIC AGENT OF ACUTE MYELOID LEUKEMIA CONTAINING 1,3,7-TRISUBSTITUTED 3,4-DIHYDROPYRIMIDO[4,5-D]PYRIMIDINE-2(1H)-ONE DERIVATIVES | GAK, DCK, NRAS | HRH4 2271/4885HRH3 2150/4885HTR3A 4426/4885 |
| US-20180009789-A1 | SUBSTITUTED BENZIMIDAZOLIUM COMPOUNDS USEFUL IN THE TREATMENT OF RESPIRATORY DISEASES | F12, CKMT1A; CKMT1B, CHRM1 | HRH4 10/4885HRH3 70/4885HTR3A 2632/4885 |
| US-11040981-B2 | Pyrrolotriazine compounds and methods of inhibiting TAM kinases | PLK2, MAP3K5, CAMKK2 | HRH4 1771/4885HRH3 1973/4885HTR3A 1752/4885 |
| US-20030153568-A1 | Benzothiazole derivatives | TK1, FLT1, CDK1 | HRH4 2262/4885HRH3 2608/4885HTR3A 3056/4885 |
| US-20030069291-A1 | 3-heterocyclylpropanohydroxamic acid PCP inhibitors | PAH, CYP2F1, CYP7A1 | HRH4 1635/4885HRH3 1604/4885HTR3A 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.